Latest Orexo News & Updates

See the latest news and media coverage for Orexo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Orexo

Pharmaceutical company developing medicines with formulation technologies

orexo.se

Headquarters: Fyrislund, Sweden
Founded year: 1995
Company type: Public company
Number of employees: 80–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Orexo

In short: Orexo divested U.S. rights for Zubsolv for $91 million and reached a $4 million non-binding settlement with the U.S. DOJ.

Company announcements

September 10 Orexo

Orexo receives additional funding to extend OX390 development

BARDA provides $2.99 million to extend the initial development phase for OX390 through 2027, increasing total contract value to $53.8 million.

September 1 Orexo

Orexo announces CFO Fredrik Järrsten's resignation effective December 2026

Järrsten departs to pursue investment advisory roles after leading key financial milestones and corporate restructuring. His exit enables administrative cost optimization as Orexo streamlines operations.

July 16 Orexo

Orexo provides Q2 2026 business update and financing plans

The company advances OX640, Izipry, and OX390 trials, initiates financing with DNB Carnegie, and continues DOJ negotiations while restructuring.

July 16 Orexo

Orexo reports Q2 2026 interim results

Total net revenues were SEK 3.5 million with a net loss of SEK 102.5 million, while advancing pipeline programs including Izipry and OX640.

Media coverage

September 14 The Globe and Mail

Orexo Wins FDA Green Light to Advance Needle‑Free Anaphylaxis Treatment OX640

An announcement from Orexo AB ( ) is now available. Orexo AB has secured U.S. FDA acceptance of its Investigational New Drug application for OX640...

September 9 ZoneBourse

Orexo secures an additional $3 million in funding for its emergency opioid overdose treatment

Orexo's US subsidiary has received an additional $3 million from the Biomedical Advanced Research and Development Authority for the project...

September 3 Investing.com

Pro-research on ORX (English)

How did Orexo AB react to the company's latest earnings report? Orexo AB reported an EPS surprise of -37.5% and a revenue surprise of -65.35%, by comparing...

September 2 BigGo Finance

Orexo CEO Sørensen: Nasal Powder Beats Needles and Pills — FDA Filing for Overdose Rescue Due Within Weeks

Orexo CEO Nikolaj Sørensen is making a bold bet: that a dry powder puffed into the nose can replace injections, daily tablets ...

Never miss news about Orexo

Track Orexo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Orexo competitors & trending companies

Browse news for competitors to Orexo and other trending companies.